HNWAG
WHWK

High Net Worth Advisory Group’s Whitehawk Therapeutics WHWK Stock Holding History

High Net Worth Advisory Group’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$12.8K – 603
2022
Q4 		$12.8K Buy
+1,000
New +$13.1K 0.01% 480

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

High Net Worth Advisory Group's WHWK Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Whitehawk Therapeutics (WHWK) in Q1 2023, closing a stake of 1,000 shares — an estimated $12.8K sold.

High Net Worth Advisory Group first reported a position in WHWK in Q4 2022 and held it in 1 quarter. The position peaked at $12.8K in Q4 2022. 70 funds tracked by Wall St. Rank hold WHWK as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Whitehawk Therapeutics position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Whitehawk Therapeutics shares in Q1 2023, an estimated $12.8K.
  • High Net Worth Advisory Group first reported a position in Whitehawk Therapeutics in Q4 2022 and held it in 1 quarter.
  • High Net Worth Advisory Group's Whitehawk Therapeutics position peaked at $12.8K in Q4 2022.
  • 70 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.